{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:07:23Z","timestamp":1788952043676,"version":"build-2803163510"},"reference-count":73,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clbc.2026.07.017","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:26:06Z","timestamp":1784301966000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metformin as a Neoadjuvant to Chemotherapy in Locally Advanced and Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0212-2982","authenticated-orcid":false,"given":"Nada G.","family":"Hamam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0352-4225","authenticated-orcid":false,"given":"Mahmoud","family":"Samir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nereen A.","family":"Almosilhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad Mahmoud","family":"Whdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar A.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Mohsen","family":"Helal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clbc.2026.07.017_bib0001","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.clbc.2026.07.017_bib0002","first-page":"438","article-title":"Breast cancer statistics, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.clbc.2026.07.017_bib0003","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.07.017_bib0004","unstructured":"Cancer Statistics Review, 1975-2017 - SEER Statistics. https:\/\/seer.cancer.gov\/archive\/csr\/1975_2017\/index.html. Accessed March 10, 2026."},{"issue":"9938","key":"10.1016\/j.clbc.2026.07.017_bib0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"The Lancet"},{"key":"10.1016\/j.clbc.2026.07.017_bib0006","doi-asserted-by":"crossref","DOI":"10.1177\/1178223420980377","article-title":"Neoadjuvant chemotherapy for breast cancer: past, present, and future","volume":"14","author":"Asaoka","year":"2020","journal-title":"Breast Cancer (Auckl)"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.017_bib0007","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/ajco.12748","article-title":"Metastatic triple negative breast cancer: optimizing treatment options, new and emerging targeted therapies","volume":"14","author":"Khosravi-Shahi","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2026.07.017_bib0008","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.2337\/dc09-1791","article-title":"Long-term metformin use is associated with decreased risk of breast cancer","volume":"33","author":"Bodmer","year":"2010","journal-title":"Diabetes Care"},{"issue":"7503","key":"10.1016\/j.clbc.2026.07.017_bib0009","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.017_bib0010","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.3747\/co.24.3380","article-title":"Metformin and breast cancer stage at diagnosis: a population-based study","volume":"24","author":"Lega","year":"2017","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clbc.2026.07.017_bib0011","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-nutr-071812-161148","article-title":"AMP-activated protein kinase: maintaining energy homeostasis at the cellular and whole-body levels","volume":"34","author":"Hardie","year":"2014","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.clbc.2026.07.017_bib0012","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.2147\/DDDT.S141675","article-title":"Metformin: a review of its potential indications","volume":"11","author":"Wang","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.017_bib0013","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrc3215","article-title":"The insulin and insulin-like growth factor receptor family in neoplasia: an update","volume":"12","author":"Pollak","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clbc.2026.07.017_bib0014","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.freeradbiomed.2022.01.010","article-title":"Metformin inhibits the tumor-promoting effect of low-dose resveratrol, and enhances the anti-tumor activity of high-dose resveratrol by increasing its reducibility in triple negative breast cancer","volume":"180","author":"Cheng","year":"2022","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"10.1016\/j.clbc.2026.07.017_bib0015","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1073\/pnas.1417636112","article-title":"Immune-mediated antitumor effect by type 2 diabetes drug, metformin","volume":"112","author":"Eikawa","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"10.1016\/j.clbc.2026.07.017_bib0016","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1158\/0008-5472.CAN-09-2994","article-title":"Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission","volume":"69","author":"Hirsch","year":"2009","journal-title":"Cancer Res"},{"issue":"86","key":"10.1016\/j.clbc.2026.07.017_bib0017","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.26286","article-title":"A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study","volume":"9","author":"Martin-Castillo","year":"2018","journal-title":"Oncotarget"},{"issue":"20","key":"10.1016\/j.clbc.2026.07.017_bib0018","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.2022.6147","article-title":"Effect of Metformin vs Placebo on invasive disease\u2013free survival in patients with breast cancer: the MA.32 randomized clinical trial","volume":"327","author":"Goodwin","year":"2022","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.clbc.2026.07.017_bib0019","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1634\/theoncologist.2017-0465","article-title":"A randomized Phase II study of Metformin plus Paclitaxel\/Carboplatin\/Bevacizumab in patients with chemotherapy-na\u00efve advanced or metastatic nonsquamous non-small cell lung cancer","volume":"23","author":"Marrone","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2026.07.017_bib0020","doi-asserted-by":"crossref","unstructured":"Goodwin PJ, Ennis M, Cescon DW, et al. Metformin addition to chemotherapy in refractory triple-negative metastatic breast cancer: a randomized phase II study. Cancer Res 79(4 Suppl):Abstract P1-16-03.","DOI":"10.1158\/1538-7445.SABCS18-P1-16-03"},{"key":"10.1016\/j.clbc.2026.07.017_bib0021","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.phrs.2019.01.036","article-title":"The effect of metformin on biomarkers and survivals for breast cancer \u2013 a systematic review and meta-analysis of randomized clinical trials","volume":"141","author":"Zhang","year":"2019","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/j.clbc.2026.07.017_bib0022","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/14737140.2022.2051482","article-title":"Factors influencing the anticancer effects of metformin on breast cancer outcomes: a systematic review and meta-analysis","volume":"22","author":"Barakat","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clbc.2026.07.017_bib0023","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.017_bib0024","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-020-0897-3","article-title":"Software tools to support title and abstract screening for systematic reviews in healthcare: an evaluation","volume":"20","author":"Harrison","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clbc.2026.07.017_bib0025","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (Updated August 2023). version 6.4","author":"Higgins","year":"2023"},{"issue":"6","key":"10.1016\/j.clbc.2026.07.017_bib0026","first-page":"1245","article-title":"Added metformin to systematic neoadjuvant chemotherapy in breast cancer patients: randomized study from Egypt","volume":"89","author":"Ahmed","year":"2021","journal-title":"Med J Cairo Univ"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.017_bib0027","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-11138-3","article-title":"The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial","volume":"12","author":"Barakat","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.017_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-021-01599-3","article-title":"The effect of metformin when combined with neoadjuvant chemotherapy in breast cancer patients","volume":"39","author":"El-khayat","year":"2021","journal-title":"Med Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.017_bib0029","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10549-022-06821-y","article-title":"Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial","volume":"197","author":"Huang","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.017_bib0030","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10549-018-05070-2","article-title":"Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial","volume":"174","author":"Nanni","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2026.07.017_bib0031","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.breast.2019.08.003","article-title":"A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy","volume":"48","author":"Pimentel","year":"2019","journal-title":"Breast"},{"issue":"12","key":"10.1016\/j.clbc.2026.07.017_bib0032","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1111\/bcp.16193","article-title":"A randomized controlled study of neoadjuvant metformin with chemotherapy in nondiabetic breast cancer women: the METNEO study","volume":"90","author":"Serageldin","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clbc.2026.07.017_bib0033","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/536145","article-title":"Assessment of pathological response of breast carcinoma in modified radical mastectomy specimens after neoadjuvant chemotherapy","volume":"2015","author":"Vasudevan","year":"2015","journal-title":"Int J Breast Cancer"},{"issue":"4","key":"10.1016\/j.clbc.2026.07.017_bib0034","first-page":"1121","article-title":"Clinical endpoints in oncology \u2013 a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.017_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.11613\/BM.2021.010502","article-title":"Sample size, power and effect size revisited: simplified and practical approaches in pre-clinical, clinical and laboratory studies","volume":"31","author":"Serdar","year":"2021","journal-title":"Biochem Med (Zagreb)"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.017_bib0036","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jclinepi.2003.08.009","article-title":"Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test","volume":"57","author":"Brookes","year":"2004","journal-title":"J Clin Epidemiol"},{"issue":"20","key":"10.1016\/j.clbc.2026.07.017_bib0037","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1200\/JCO.2009.19.6410","article-title":"Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer","volume":"27","author":"Jiralerspong","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clbc.2026.07.017_bib0038","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s11605-022-05354-5","article-title":"Association of tumor pathological response with the use of Metformin during neoadjuvant chemoradiotherapy in rectal and esophageal\/gastroesophageal cancer patients: a systematic review and meta-analysis","volume":"26","author":"Sakamoto","year":"2022","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.017_bib0039","doi-asserted-by":"crossref","DOI":"10.1186\/s12957-023-03087-6","article-title":"Metformin increases pathological responses to rectal cancers with neoadjuvant chemoradiotherapy: a systematic review and meta-analysis","volume":"21","author":"Lai","year":"2023","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.clbc.2026.07.017_bib0040","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4137\/BCBCR.S33163","article-title":"Relevance of pathological complete response after neoadjuvant therapy for breast cancer","volume":"10","author":"Pennisi","year":"2016","journal-title":"Breast Cancer (Auckl)"},{"issue":"5","key":"10.1016\/j.clbc.2026.07.017_bib0041","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ctrv.2015.03.002","article-title":"Metformin and breast cancer: basic knowledge in clinical context","volume":"41","author":"Pizzuti","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"Pt A","key":"10.1016\/j.clbc.2026.07.017_bib0042","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.phrs.2016.10.006","article-title":"Metformin: an anti-diabetic drug to fight cancer","volume":"113","author":"Daugan","year":"2016","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.017_bib0043","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00280-016-3037-3","article-title":"Combinational strategies of metformin and chemotherapy in cancers","volume":"78","author":"Zhang","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.clbc.2026.07.017_bib0044","article-title":"Metformin: from diabetes to cancer-unveiling molecular mechanisms and therapeutic strategies","volume":"13","author":"Amengual-Cladera","year":"2024","journal-title":"Biology (Basel)"},{"issue":"4","key":"10.1016\/j.clbc.2026.07.017_bib0045","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10059-013-0169-8","article-title":"Metabolic roles of AMPK and metformin in cancer cells","volume":"36","author":"Choi","year":"2013","journal-title":"Mol Cells"},{"issue":"25","key":"10.1016\/j.clbc.2026.07.017_bib0046","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1038\/sj.onc.1211024","article-title":"The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level","volume":"27","author":"Sahra I","year":"2008","journal-title":"Oncogene"},{"issue":"14","key":"10.1016\/j.clbc.2026.07.017_bib0047","doi-asserted-by":"crossref","first-page":"6745","DOI":"10.1158\/0008-5472.CAN-06-4447","article-title":"Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth","volume":"67","author":"Buzzai","year":"2007","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.017_bib0048","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1042\/BJ20080557","article-title":"Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice","volume":"412","author":"Huang","year":"2008","journal-title":"Biochem J"},{"issue":"8\u20139","key":"10.1016\/j.clbc.2026.07.017_bib0049","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.exger.2005.07.007","article-title":"Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2\/neu transgenic mice","volume":"40","author":"Anisimov","year":"2005","journal-title":"Exp Gerontol"},{"issue":"10","key":"10.1016\/j.clbc.2026.07.017_bib0050","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1158\/1078-0432.CCR-12-2935","article-title":"The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement","volume":"19","author":"Villaruz","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.017_bib0051","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/SLA.0000000000003286","article-title":"Conditional survival in patients with rectal cancer and complete clinical response managed by watch and wait after chemoradiation: recurrence risk over time","volume":"272","author":"S\u00e3o Juli\u00e3o","year":"2020","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.clbc.2026.07.017_bib0052","doi-asserted-by":"crossref","first-page":"376","DOI":"10.4048\/jbc.2014.17.4.376","article-title":"Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients","volume":"17","author":"Luangdilok","year":"2014","journal-title":"J Breast Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.017_bib0053","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3393\/ac.2024.00339.0048","article-title":"Is clinical complete response as accurate as pathological complete response in patients with mid-low locally advanced rectal cancer?","volume":"41","author":"Shadmanov","year":"2025","journal-title":"Ann Coloproctol"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.017_bib0054","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1097\/JS9.0000000000001060","article-title":"Breast-conserving surgery is associated with a lower incidence of suicide among females with breast cancer in the United States: a population-based retrospective cohort study","volume":"110","author":"Guo","year":"2024","journal-title":"Int J Surg"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.017_bib0055","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10549-022-06579-3","article-title":"Breast-conserving surgery with whole breast radiation therapy has a subsequent lower mood disorder incidence rate than total mastectomy in early-stage breast cancer patients: a nationwide population-based longitudinal study","volume":"193","author":"Liao","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.clbc.2026.07.017_bib0056","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamasurg.2020.3325","article-title":"Association of breast cancer surgery with quality of life and psychosocial well-being in young breast cancer survivors","volume":"155","author":"Rosenberg","year":"2020","journal-title":"JAMA Surg"},{"issue":"24","key":"10.1016\/j.clbc.2026.07.017_bib0057","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph16244970","article-title":"Comparing quality of life in breast cancer patients who underwent mastectomy versus breast-conserving surgery: a meta-analysis","volume":"16","author":"Ng","year":"2019","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.017_bib0058","doi-asserted-by":"crossref","DOI":"10.1186\/s12957-017-1273-6","article-title":"Oncological outcome of complete response after neoadjuvant chemotherapy for breast conserving surgery: a systematic review and meta-analysis","volume":"15","author":"Li","year":"2017","journal-title":"World J Surg Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.017_bib0059","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/10600280211025792","article-title":"Efficacy of Metformin in patients with breast cancer receiving chemotherapy or endocrine therapy: systematic review and meta-analysis","volume":"56","author":"Morio","year":"2022","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clbc.2026.07.017_bib0060","article-title":"A systematic review and meta-analysis on the efficacy and safety of metformin as adjunctive therapy among women with metastatic breast cancer","volume":"29","author":"Lusica","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.clbc.2026.07.017_bib0061","article-title":"Metformin reduces the clonal fitness of Dnmt3a R878H hematopoietic stem and progenitor cells by reversing their aberrant metabolic and epigenetic state","author":"Hosseini","year":"2024","journal-title":"Res Sq"},{"issue":"24","key":"10.1016\/j.clbc.2026.07.017_bib0062","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1182\/blood-2015-11-683490","article-title":"Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice","volume":"128","author":"Zhang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clbc.2026.07.017_bib0063","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.freeradbiomed.2015.05.045","article-title":"Metformin ameliorates ionizing irradiation-induced long-term hematopoietic stem cell injury in mice","volume":"87","author":"Xu","year":"2015","journal-title":"Free Radic Biol Med"},{"issue":"12","key":"10.1016\/j.clbc.2026.07.017_bib0064","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.4252\/wjsc.v12.i12.1455","article-title":"Effect of metformin on stem cells: molecular mechanism and clinical prospect","volume":"12","author":"Jiang","year":"2020","journal-title":"World J Stem Cells"},{"key":"10.1016\/j.clbc.2026.07.017_bib0065","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1044030","article-title":"Gut microbiota is correlated with gastrointestinal adverse events of metformin in patients with type 2 diabetes","volume":"13","author":"Huang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.017_bib0066","article-title":"Metformin-induced chronic diarrhea misdiagnosed as irritable bowel syndrome for years","volume":"16","author":"Chaudhary","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.017_bib0067","doi-asserted-by":"crossref","first-page":"21","DOI":"10.14740\/jem327w","article-title":"Late-onset chronic severe painless diarrhea secondary to metformin: case report and literature review","volume":"6","author":"Lowry","year":"2016","journal-title":"J Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.clbc.2026.07.017_bib0068","doi-asserted-by":"crossref","DOI":"10.3390\/ph14040329","article-title":"Metformin modifies the gut microbiota of mice infected with Helicobacter pylori","volume":"14","author":"Jauvain","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"10.1016\/j.clbc.2026.07.017_bib0069","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1634\/theoncologist.2015-0096","article-title":"Metformin use is associated with better survival of breast cancer patients with diabetes: a meta-analysis","volume":"20","author":"Xu","year":"2015","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.clbc.2026.07.017_bib0070","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae283","article-title":"Breast cancer incidence and mortality, by age, stage and molecular subtypes, by race\/ethnicity in Canada","volume":"30","author":"Wilkinson","year":"2025","journal-title":"Oncologist"},{"issue":"27","key":"10.1016\/j.clbc.2026.07.017_bib0071","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1200\/JCO.2015.65.8013","article-title":"Subtype-dependent relationship between young age at diagnosis and breast cancer survival","volume":"34","author":"Partridge","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.07.017_bib0072","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.breast.2021.12.006","article-title":"The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: a U.S. SEER database analysis","volume":"61","author":"Kim","year":"2021","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.017_bib0073","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-6696-8","article-title":"Age-related differences in breast cancer mortality according to race\/ethnicity, insurance, and socioeconomic status","volume":"20","author":"San Miguel","year":"2020","journal-title":"BMC Cancer"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:08:40Z","timestamp":1788948520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926001187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":73,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1526820926001187"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.017","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin as a Neoadjuvant to Chemotherapy in Locally Advanced and Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}